329 related articles for article (PubMed ID: 35069896)
1. Biomarkers for predicting the efficacy of immune checkpoint inhibitors.
Wang C; Wang HN; Wang L
J Cancer; 2022; 13(2):481-495. PubMed ID: 35069896
[TBL] [Abstract][Full Text] [Related]
2. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
Meng X; Huang Z; Teng F; Xing L; Yu J
Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
[TBL] [Abstract][Full Text] [Related]
3. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors.
Yi M; Jiao D; Xu H; Liu Q; Zhao W; Han X; Wu K
Mol Cancer; 2018 Aug; 17(1):129. PubMed ID: 30139382
[TBL] [Abstract][Full Text] [Related]
5. Possible Biomarkers for Cancer Immunotherapy.
Otoshi T; Nagano T; Tachihara M; Nishimura Y
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31277279
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy and predictive immunologic profile: the tip of the iceberg.
Cunha Pereira T; Rodrigues-Santos P; Almeida JS; Rêgo Salgueiro F; Monteiro AR; Macedo F; Soares RF; Domingues I; Jacinto P; Sousa G
Med Oncol; 2021 Mar; 38(5):51. PubMed ID: 33788049
[TBL] [Abstract][Full Text] [Related]
7. Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: A systematic review and meta-analysis.
Zou Y; Hu X; Zheng S; Yang A; Li X; Tang H; Kong Y; Xie X
EBioMedicine; 2021 Jan; 63():103137. PubMed ID: 33310681
[TBL] [Abstract][Full Text] [Related]
8. Optimizing cancer immunotherapy: Is it time for personalized predictive biomarkers?
Music M; Prassas I; Diamandis EP
Crit Rev Clin Lab Sci; 2018 Nov; 55(7):466-479. PubMed ID: 30277835
[TBL] [Abstract][Full Text] [Related]
9. Advances and prospects of biomarkers for immune checkpoint inhibitors.
Yamaguchi H; Hsu JM; Sun L; Wang SC; Hung MC
Cell Rep Med; 2024 Jun; ():101621. PubMed ID: 38906149
[TBL] [Abstract][Full Text] [Related]
10. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
Front Immunol; 2021; 12():646874. PubMed ID: 33927719
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients.
Duffy MJ; Crown J
Clin Chem; 2019 Oct; 65(10):1228-1238. PubMed ID: 31315901
[TBL] [Abstract][Full Text] [Related]
12. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.
Gjoerup O; Brown CA; Ross JS; Huang RSP; Schrock A; Creeden J; Fabrizio D; Tolba K
AAPS J; 2020 Oct; 22(6):132. PubMed ID: 33057937
[TBL] [Abstract][Full Text] [Related]
13. The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer.
Xu Y; Zuo F; Wang H; Jing J; He X
Front Immunol; 2022; 13():1045957. PubMed ID: 36389711
[TBL] [Abstract][Full Text] [Related]
14. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.
Krieger T; Pearson I; Bell J; Doherty J; Robbins P
Diagn Pathol; 2020 Jan; 15(1):6. PubMed ID: 32000815
[TBL] [Abstract][Full Text] [Related]
15. Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges.
Yang F; Wang JF; Wang Y; Liu B; Molina JR
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008273
[TBL] [Abstract][Full Text] [Related]
16. Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy.
Song Y; Li Z; Xue W; Zhang M
Immunotherapy; 2019 Apr; 11(6):515-529. PubMed ID: 30860441
[TBL] [Abstract][Full Text] [Related]
17. Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.
Signorelli D; Giannatempo P; Grazia G; Aiello MM; Bertolini F; Mirabile A; Buti S; Vasile E; Scotti V; Pisapia P; Cona MS; Rolfo C; Malapelle U;
Biomed Res Int; 2019; 2019():9056417. PubMed ID: 31179334
[TBL] [Abstract][Full Text] [Related]
18. Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer.
Czink E; Kloor M; Goeppert B; Fröhling S; Uhrig S; Weber TF; Meinel J; Sutter C; Weiss KH; Schirmacher P; Doeberitz MVK; Jäger D; Springfeld C
Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28619747
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers for immune checkpoint inhibitors in solid tumors.
Kapoor V; Kelly WJ
Clin Transl Oncol; 2023 Jan; 25(1):126-136. PubMed ID: 36103047
[TBL] [Abstract][Full Text] [Related]
20. Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs).
Giustini N; Bazhenova L
Lung Cancer (Auckl); 2021; 12():21-34. PubMed ID: 33790679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
